AMLX · Amylyx Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$27.70
-0.09 (-0.31%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$3.33B
Shares
111.42M
Volume · Oct 6
732.21K
Avg daily vol (3M)
2.3M
Amylyx Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Amylyx Pharmaceuticals, Inc. (AMLX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲21.1%
$345,000
−$53.76M
'22 Q3
22-11-10
·
$71.43M
$1.57M
'23 Q1
23-05-11
·
$98.22M
$22.07M
'23 Q2
23-08-10
▲29666.1%
$102.69M
$20.89M
'23 Q3
23-11-09
·
$108.45M
$4.73M
'23 Q4
24-02-22
▲24.1%
$88.64M
−$118.79M
'24 Q1
24-05-09
▼101%
$
−$72.70M
'24 Q2
24-08-08
▼99.6%
$416,000
−$72.70M
'24 Q3
24-11-07
▼100.6%
$
−$37.55M
'24 Q4
25-03-04
▼100%
$
−$35.91M
'25 Q1
25-05-08
·
$
−$41.44M
'25 Q2
25-08-07
▼100%
$
−$34.39M
'25 Q3
25-11-06
LATEST
·
$
−$33.00M
'25 Q4
26-03-03
Earnings call
FY26 · Q2
2026-08-06
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call
Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
Confident tone
AMX0114 in ALS (LUMINA trial)
Avexitide pivotal LUCIDITY Phase III trial
Commercial launch readiness for avexitide
Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Confident tone
ALS program AMX114 / LUMINA trial
PBH unmet need and market opportunity
Avexatide pivotal Phase III LUCIDITY trial
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript
Positive tone
Avexitide LUCIDITY Phase III Trial
AMX0114 in ALS (LUMINA Trial)
Regulatory Engagement and Trial Design
Revenue
$
▼ 100% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
Confident tone
Avexitide / PBH lead program
AMX0114 in ALS
AMX0035 in PSP (ORION trial)
Revenue
$
Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript
Confident tone
Avexitide / LUCIDITY Phase 3 in post-bariatric hypoglycemia
AMX0114 in ALS (LUMINA Phase 1)
AMX0035 in progressive supranuclear palsy (ORION)
Revenue
$
▼ 100% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript
Confident tone
Avexitide LUCIDITY Phase III in PBH
AMX0114 in ALS (LUMINA)
AMX0035 in PSP (ORION)
Revenue
$*
▼ 100.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript
Positive tone
Avexitide Phase III in PBH
AMX0114 in ALS (LUMINA)
AMX0035 in PSP (ORION)
Revenue
$416,000
▼ 99.6% YoY Diluted EPS
$-1.07
▼ 456.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript
Positive tone
Avexitide for post-bariatric hypoglycemia (PBH)
AMX0114 in ALS
Regulatory engagement and trial design
Revenue
$
▼ 101% YoY Diluted EPS
$-1.07
▼ 445.2% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript
Cautious tone
AMX0114 / Calpain-2 ALS antisense program
PHOENIX trial failure and restructuring
PSP (AMX0035) program
Revenue
$88.64M
▲ 24.1% YoY Diluted EPS
$-1.75
▼ 8850% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript
Positive tone
PHOENIX Phase 3 trial readout
RELYVRIO commercial launch and growth initiatives
Pipeline expansion in neurodegenerative diseases
Revenue
$108.45M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2023 Earnings Call Transcript
Revenue
$102.69M
▲ 29666.1% YoY Diluted EPS
$0.30
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2023 Earnings Call Transcript
Revenue
$98.22M
Diluted EPS
$0.31
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2023 Earnings Call Transcript
Revenue
$71.43M
Diluted EPS
$0.02
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2022 Earnings Call Transcript
Revenue
$345,000
▲ 21.1% YoY Diluted EPS
$-0.92
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 webcasts